<div class="white-sheet">
	<div class="content-slide">


		<div class="title-bar red"></div>

		<div class="wrapper slide-3-4-4">


			<div class="popups" style="position:absolute">
				<div data-effect="fade" data-duration="1000" data-target="references-overlay" data-width="600" data-height="490" class="references-button show-overlay"></div>
				<div data-effect="fade" data-duration="1000" data-target="information-overlay" data-width="600" data-height="490" class="information-button show-overlay"></div>
			</div>

			<div class="slide-title red two-line">
				Eltrombopag in severe aplastic anaemia: <br />tapering and discontinuation criteria
			</div>


			<div class="content-container">

				<img style="margin-top:40px" class="center-img" src="media/images/slide_3-4-4/picture1.png" alt="">
			</div>

		</div>


		<div class="information-overlay overlay">

			<header>Eltrombopag in severe aplastic anaemia: tapering and discontinuation criteria</header>
				
			<ul>
				<li><span>Tapering in multilineage responders</span>
					<ul>
						<li><span>Once platelet count is >50×10<sup>9</sup>/l, haemoglobin level is >10 g/dl in the absence of RBC transfusions and ANC is >1×10<sup>9</sup>/l for more than 8 weeks, the dose of eltrombopag should be reduced by up to 50%</span></li>
						<li><span>If counts stay stable after 8 weeks at the reduced dose, then discontinue eltrombopag and monitor blood counts</span></li>
						<li><span>If platelet counts drop to &lt;30×10<sup>9</sup>/l, haemoglobin to &lt;9 g/dl or ANC to &lt;0.5×10<sup>9</sup>/l, eltrombopag may be reinitiated back to the previous dose</span></li>
					</ul>
				</li>
				<li><span>Discontinuation</span>
					<ul>
						<li><span>If no haematological response has occurred after 16 weeks of therapy with eltrombopag, treatment with eltrombopag should be discontinued</span></li>
						<li><span>Excessive platelet count responses or important liver test abnormalities also necessitate discontinuation of eltrombopag</span></li>
					</ul>
				</li>
			</ul>

		</div>


		<div class="references-overlay overlay">

			<header>References</header>
				
			<ul>
				<li class="navigateHref" data-navtarget="media/documents/module2/ScheinbergP-2012-Blood-v120p1185.pdf"><span>GlaxoSmithKline. Eltrombopag tablets for oral use. Prescribing Information (draft). 2014</span></li>
			</ul>

		</div>


		

	</div>
</div>